Latuda available for the treatment of schizophrenia

Sunovion announced that Latuda (lurasidone HCl) is available for the treatment of adults with schizophrenia. Latuda, a once daily atypical antipsychotic, is a mixed dopamine D₂ and serotonin 5HT_2A receptor antagonist. It was first approved by the FDA on October 28, 2010.

Latuda is available in 40mg and 80mg dosage strength tablets.

For more information call (800) 739-0565 or visit www.latuda.com.